Loading
A phase 3 trial of Cabergoline in Pituitary tumours, run by Seth Gordhandas Sunderdas Medical College, completed.
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor is a phase 3 interventional study registered as NCT00889525 by Seth Gordhandas Sunderdas Medical College, started 2007-11. Interventions recorded: Cabergoline. Conditions recorded: Cushing's Disease, Corticotroph Adenoma.
Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Cabergoline, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.